VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Final results of BRIGHT AML 1003

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, discusses final 4-year overall survival results of BRIGHT AML 1003 (NCT01546038), a study investigating survival benefit of glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter